血细胞白血病:基因组特征及其对探索临床可操作性的潜在相关性
Meera Mohan1, Natalie Danziger2, Othman Salim Akhtar1
1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Blood advances
|February 24, 2026
概括
与多发性骨髓瘤 (MM) 相比,血细胞白血病 (PCL) 呈现出明显的遗传改变. 下一代测序确定了PCL中的特定突变和转位,提供了潜在的治疗点.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 血细胞白血病 (PCL) 是一种罕见且具有攻击性的血液性恶性瘤.
- 了解PCL的遗传情景对于开发向疗法至关重要.
研究的目的:
- 使用下一代测序 (NGS) 将血细胞白血病 (PCL) 与多发性骨髓瘤 (MM) 的遗传特征进行比较.
- 根据基因异常,识别PCL中的潜在治疗点.
主要方法:
- 下一代测序 (NGS) 在18名PCL患者的血细胞 (外周血液和骨髓) 上进行.
- 将NGS数据与1742个多发性髓瘤 (MM) 样本进行了比较.
- 分析的重点是关键基因中的突变和转位.
主要成果:
- 在PCL和MM中,TP53,CCND1和KRAS突变是常见的.
- 与MM相比,PCL显示DIS3,CCND2,PIK3R1和MAP3K1的变化频率明显更高.
- 转位,包括IGH::CCND1和IGH::MYC,在PCL中更频繁,IGH::MYC达到统计学意义.
结论:
- 与MM相比,PCL具有明显的遗传异常,特别是在DIS3,CCND2,PIK3R1,MAP3K1和IGH::MYC中.
- 诸如BRAF,CCND1,PIK3R1和RAS变化的可用药物标为PCL中生物标志物驱动的临床试验提供了机会.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Pharmacogenomics: Identification of New Drug Targets
49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Lineage Commitment
4.5K
Commitment is the process whereby stem cells:
4.5K


